Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.72 |
| ▸ | FAP | Q12884 | 9/20 | 0.72 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.72 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.72 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.72 |
| ▸ | PREP | P48147 | 7/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15028179 | 0.91 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13263479 | 0.90 | OPRM1 (0.63) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL26500576 | 0.86 | DPP4 (0.55) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30051426 | 0.86 | DPP4 (0.60) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29414524 | 0.85 | ACE (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL21746949 | 0.84 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12658496 | 0.84 | DPP4 (0.74) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL21067756 | 0.82 | DPP4 (0.61) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL21067758 | 0.82 | DPP4 (0.61) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL8072499 | 0.81 | DPP4 (0.60) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885FAP 1/4885DPP8 21/4885 |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885FAP 1/4885DPP8 21/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885FAP 1/4885DPP8 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.